BROOMFIELD, Colo. — May 6, 2026 — Leads & Copy — Aclarion, Inc. (Nasdaq: ACON, ACONW) has granted Daniel Keefe, the recently appointed Commercial Director, Western U.S., an inducement stock option to acquire 17,000 shares of the company’s common stock.
The compensation committee of Aclarion’s board of directors approved the stock option on May 5, 2026, as an inducement for Keefe’s employment. The grant adheres to Nasdaq Listing Rule 5635(c)(4).
The option’s exercise price is set at $3.20 per share, equivalent to Aclarion’s common stock closing price on the grant date. Vesting will occur as to one-fourth of the options on the first anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the subsequent three years, contingent upon Keefe’s continued service with Aclarion.
The stock option has a 10-year term and is subject to the terms and conditions of an inducement stock option agreement.
Aclarion is a healthcare technology company focused on optimizing clinical treatments through Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms. The company’s Nociscan platform aims to assist physicians in identifying the location of chronic low back pain and improve treatment success rates. Nociscan is a SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine.
Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
Source: Aclarion, Inc.
